MedTrace Logo

Nordic Luveris Study

NCT00553293 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 526

Last updated 2007-11-05

No results posted yet for this study

Summary

To study whether addition of human LH hormone (Luveris) during the final days of stimulation with recombinant FSH (Gonal-f) for controlled ovarian stimulation will be of benefit for patients undergoing in vitro fertilisation.

Conditions

Interventions

DRUG

recombinant luteinizing hormone (Luveris)

75 iu/day form cycle day 6

DRUG

recombinant follicle stimulating hormone (Gonal-f)

rFSH 150 iu/day

Sponsors & Collaborators

  • Regionshospitalet Viborg, Skive

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Helse Fonna

    collaborator OTHER

  • Turku Hospital

    collaborator UNKNOWN

  • Odense University Hospital

    collaborator OTHER

  • Herlev Hospital

    collaborator OTHER

  • Holbaek Sygehus

    collaborator OTHER

  • Hvidovre University Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Anders N Andersen, professor · Fertility Clinic Rigshospitalet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2004-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00553293 on ClinicalTrials.gov